

ABSTRACT

A hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula polymorpha cells. 10^8 cells contain 6-10 μ g HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula polymorpha cells as an adjuvant.